Insights On Manufacturing Logistics

31. AST Origins: Pioneering RTU Flexibility With Robotic Fill-Finish Systems 3/25/2026

    Modernize sterile manufacturing with robotic fill-finish systems. Achieve multi-format flexibility and risk reduction to meet the rigorous demands of personalized medicine and small-batch production.

32. Robotics And AI In Pharma: Driving The Next Wave Of Innovation 2/23/2026

    Adopting AI and robotics enhance sterility and regulatory compliance and enable real-time decision-making and reduce human-borne contamination, ensuring the safe production of complex therapies.

33. Selecting A Prefillable Syringe System With Confidence 2/5/2026

    Discover an advancement in the prefillable syringe market, uniquely integrating the syringe barrel, plunger, and needle shield/tip cap into a fully harmonized, verified system from a single supplier.

34. Protecting Biopharma Manufacturing Supply Chains 2/5/2026

    In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers and staying agile during periods of change in the industry.

35. Building Resilience In Biomanufacturing Operations 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanufacturing, which in part requires agility and preparation for the worst-case scenario. The panel was in agreement that earlier-phase companies have the highest opportunity to bake resilience into their operations.

36. How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets? 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also discuss the short- to long-term impact of efforts to onshore biomanufacturing.

37. How Is U.S. Policy Reshaping Global Biomanufacturing Operations? 2/5/2026

    In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the global operating environment.

38. Extractables And Leachables: A Critical Part Of CCS Under EU GMP Annex 1 2/4/2026

    Managing chemical migration from packaging and process equipment is essential to protect patient safety, maintain drug stability, and ensure regulatory compliance.

39. FAQs On The Revised EU GMP Annex 1: Volume 7 2/4/2026

    Modernize your sterile manufacturing approach. Explore essential insights on contamination control strategies, risk management, and barrier technologies to ensure full regulatory alignment.

40. FAQs On The Revised EU GMP Annex 1: Volume 8 2/4/2026

    Successfully implementing a site-wide CCS requires prioritizing barrier technologies, integrating primary packaging into risk assessments, and adopting a data-driven approach to environmental monitoring.